Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short-term Investments (2020 - 2026)

10x Genomics' Short-term Investments history spans 6 years, with the latest figure at $49.4 million for Q4 2025.

  • On a quarterly basis, Short-term Investments changed 0.22% to $49.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.4 million, a 0.22% change, with the full-year FY2025 number at $49.4 million, changed 0.22% from a year prior.
  • Short-term Investments hit $49.4 million in Q4 2025 for 10x Genomics, roughly flat from $49.6 million in the prior quarter.
  • Over the last five years, Short-term Investments for TXG hit a ceiling of $226.8 million in Q1 2022 and a floor of $28000.0 in Q3 2021.
  • Historically, Short-term Investments has averaged $51.7 million across 5 years, with a median of $39.4 million in 2023.
  • Biggest five-year swings in Short-term Investments: tumbled 99.95% in 2021 and later skyrocketed 780025.0% in 2022.
  • Tracing TXG's Short-term Investments over 5 years: stood at $28000.0 in 2021, then soared by 9303.57% to $2.6 million in 2022, then soared by 1017.01% to $29.4 million in 2023, then skyrocketed by 67.74% to $49.3 million in 2024, then increased by 0.22% to $49.4 million in 2025.
  • Business Quant data shows Short-term Investments for TXG at $49.4 million in Q4 2025, $49.6 million in Q3 2025, and $49.5 million in Q2 2025.